Koers Shanghai Pharmaceuticals Holding Co., Ltd Other OTC
Aandelen
SHPMY
US81943R1005
Farmaceutische producten
Omzet 2024 * | 288 mld. 39,82 mld. 36,59 mld. | Omzet 2025 * | 317 mld. 43,77 mld. 40,21 mld. | Marktkapitalisatie | 61,18 mld. 8,45 mld. 7,76 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 4,83 mld. 667 mln. 613 mln. | Nettowinst (verlies) 2025 * | 5,84 mld. 806 mln. 741 mln. | EV/omzet 2024 * | 0,26 x |
Nettoschuld 2024 * | 13,27 mld. 1,83 mld. 1,68 mld. | Nettoschuld 2025 * | 19,41 mld. 2,68 mld. 2,46 mld. | EV/omzet 2025 * | 0,25 x |
K/w-verhouding 2024 * |
12,9
x | K/w-verhouding 2025 * |
11,4
x | Werknemers | - |
Dividendrendement 2024 * |
2,79% | Dividendrendement 2025 * |
3,46% | Vrij verhandelbaar | 38,5% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Yong Zhong Li
PSD | President | 54 | 27-06-19 |
Bo Shen
PSD | President | 51 | 05-06-13 |
Ye Lu
IRC | Investor Relations Contact | 35 | 01-01-16 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Bo Shen
PSD | President | 51 | 05-06-13 |
Yong Zhong Li
PSD | President | 54 | 27-06-19 |
Manson Fok
BRD | Director/Board Member | 67 | 27-06-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+23,18% | 74,04 mld. | |
-1,79% | 24,18 mld. | |
+3,42% | 8,46 mld. | |
-23,66% | 7,64 mld. | |
+13,06% | 5,33 mld. | |
+2,27% | 4,12 mld. | |
-6,90% | 3,92 mld. | |
+3,99% | 3,89 mld. | |
+19,43% | 3,54 mld. |